Once-a-Week Insulin Shot Could Help Growing Diabetes Patient Base and Spell Huge Profits for Investors
LOS ANGELES, CA -- (Marketwire) -- 02/22/13 -- In January 2013, newly trading AntriaBio, Inc. (OTCQB: ANTB) acquired one of the most-interesting and buzzworthy assets we've seen in some time from a private company called PR Pharmaceuticals.
AntriaBio swooped in to snag the intriguing lead diabetes product, AB101, after that firm had already invested more than $100 million into the formulation, manufacturing and intellectual property development of the injectable once-a-week basal insulin solution for diabetics who are otherwise forced to take shots on a daily basis.
The team at AntriaBio was getting a great deal of attention at the recent Healthcare Conferences in San Francisco -- well before the company was even publicly trading as it is now. Why? Not only because the lead product had already seen substantial private capital development investment, but also because AB101 offers potential significant advantages over basal insulin products offered by Sanofi-Aventis and Novo Nordisk; whose products Lantus and Levemir have a combined $8B in annual sales.
From an investment standpoint, we like AntriaBio because the value for the lead product is clearly established but has not yet been recognized by the public markets. As their story begins to spread and more analysts begin to recognize its value, the stock price of this very-low-float company should begin to increase.
Looking at the situation from an industry standpoint, we have seen dozens of stories and several examples of industry titans buying once discarded unique assets with substantial market potential, for big money. See Amgen's acquisition of deCODE Genetics for $415MM in December 2012 as one.
"The company (deCODE) declared bankruptcy in 2009 and was rescued by some of its original investors, who acquired the firm and its assets for around $14 million and went on to invest another roughly $45 million."
These biotechnologies were bought for pennies on the dollar and once their true value came to be recognized the acquisitions led to substantial profits.
The same should hold true for AntriaBio -- especially given that the incidence of diabetes is increasing rapidly and that this one-a-week insulin replacement therapy could be very appealing to individuals with diabetes who need to mimic healthy pancreas function by delivering insulin consistently day and night (basal insulin) and as needed following meals (bolus insulin).
In fact, if approved, AntriaBio believes AB101 will result in greater patient compliance (once weekly delivery versus once daily). Keep in mind, also, that the number of just over 300 million individuals with diabetes is expected to grow to be 550 million by 2030.
AntriaBio proposes that AB101 would be administered by subcutaneous injection and targets patients with type 1 and type 2 diabetes who require basal insulin for the control of hyperglycemia. The formulation has been designed to release insulin slowly and uniformly over a period of approximately one week without an adverse initial burst of insulin. The release profile results in a low and sustained insulin level that supplements the effects of bolus insulin and complements the effects of other diabetes medications.
The firm has a very smart and efficient clinical approval pathway that includes for the possibility that AB101 may be able to be marketed in Russia while US and EU studies move forward at a slower pace.
This is a fascinating and innovative technology led by a group with plenty of product experience and we will follow this story as it unfolds.
In the meantime, given the share-count actually in the float currently, it may be wise for both traders and long-term holders to consider establishing positions in front of upcoming catalysts and before this marked biotech's popularity begins to spread.
Disclosure: Author M.E. Garza is Long ANTB
The full version of this report complete with presentation slide deck images chart can be found here:
Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com
Media Contacts Only:
e-mail: Email Contact